Annexon Inc., of South San Francisco, said it closed its IPO of 14.75 million shares at $17 each for gross proceeds of approximately $250.8 million. The underwriters have been granted a 30-day option to purchase up to an additional 2.21 million shares of common stock. Annexon’s shares are trading on Nasdaq under the ticker symbol ANNX.

Arcturus Therapeutics Holdings Inc., of San Diego, said it priced an underwritten public offering of 3.26 million shares at $53 each for gross proceeds of approximately $173 million. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 489,622 shares of common stock at the public offering price. The net proceeds will be used to develop, test and manufacture its LUNAR-COV19 vaccine candidate and to continue clinical development of LUNAR-OTC; to advance the company’s LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical development; to fund early research and development of RNA medicines; and for general corporate and working capital purposes. Shares of Arcturus (NASDAQ:ARCT) closed July 29 at $53.17, down $2.43.

Atsena Therapeutics Inc., of Durham, N.C., disclosed that it closed an $8.15 million series 1 financing in April 2020. The round was led by Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund with participation by Osage University Partners, PBM Capital and the University of Florida. The company plans to use the capital to fund development of its gene therapy targeting GUCY2D-associated Leber congenital amaurosis.

Bioxcel Therapeutics Inc., of New Haven, Conn., said it priced an underwritten public offering of 4 million shares at $50 each. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price. Gross proceeds are expected to be $200 million. Shares of Bioxcel (NASDAQ:BTAI) closed July 29 at $47.90, down $4.64.

Essa Pharma Inc., of Vancouver, British Columbia, said it priced an underwritten public offering of 7.1 million shares at $6 each for proceeds of $42.6 million. The underwriters have been granted a 30-day option to purchase up to an additional 1.06 million shares of its common shares. The net proceeds will support preclinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. Shares of Essa (NASDAQ:EPIX) closed July 29 at $6.80, up 56 cents.

Inhibrx Inc., of La Jolla, Calif., filed with the SEC to raise up to $100 million in an IPO. The number of shares and share price have not yet been disclosed. The company, founded in 2017, is developing INBRX-109, a tetravalent DR5 agonist in chondrosarcoma and mesothelioma. Upon pricing, the firm is seeking a listing on Nasdaq under the ticker INBX. Jefferies, Evercore ISI and Credit Suisse are acting as joint bookrunners for the deal. Inhibrx withdrew an earlier IPO filing looking to raise $75 million last year.

Omega Therapeutics Inc., of Cambridge, Mass., which is focused on epigenomic programming, said it completed an $85 million financing that will support progression to first-in-human clinical trials of its epigenomic controllers for programs in oncology, inflammation, autoimmune, metabolic and rare genetic diseases. The company said it has created a platform and knowledge base that identifies Insulated Genomic Domains (IGDs) and their biological functions in both healthy and diseased states across cell types. IGDs naturally function as the fundamental regulators of the human genome and can be modulated to up- or down-regulate single or multiple genes simultaneously.

Sunesis Pharmaceuticals Inc., of South San Francisco, said it priced an underwritten public offering of 52.17 million shares at 23 cents each for gross proceeds of approximately $12 million. The underwriters have been granted a 30-day option to purchase up to an additional 7.82 million shares. The company anticipates using the net proceeds to fund ongoing development of PDK1 inhibitor SNS-510 and general corporate purposes.

TCR2 Therapeutics Inc., of Cambridge, Mass., said it priced an underwritten public offering of 8 million shares of its common stock at $15.50 per share. Gross proceeds are expected to be $124 million. The company, with a pipeline of T-cell therapies for treating cancer, said it intends to use the net proceeds to advance its clinical and earlier-stage programs as well as for R&D, working capital and general corporate purposes. Jefferies, SVB Leerink, Piper Sandler and BMO Capital Markets are joint book-running managers. Suntrust Robinson Humphrey is co-manager. Shares of TCR2 (NASDAQ:TCRR) closed July 29 at $17.98, up $1.70.

Trobix Bio Ltd., of Netanya, Israel, said it closed $3 million in series A funding from its lead investor, Chartered Opus, to advance its antimicrobial resistance platform technology and continue preclinical development of its lead product, TBX-101, for treating patients with gut antimicrobial-resistant bacteria.

Vico Therapeutics BV, of Leiden, the Netherlands, said it raised $31 million in its series A financing round to advance therapies for rare CNS diseases. The funding will be used to drive its late preclinical-stage antisense oligonucleotides platform to develop therapies for treating forms of spinocerebellar ataxia and Huntington’s disease into first in-human clinical trials by late 2021. The financing was led by Life Science Partner, co-led by Kurma Partners and supported by Pontifax, Droia Genetic Disease, Polaris Partners, Pureos Bioventures and Idinvest Partners.

No Comments